Dr James Wilmott awarded for outstanding cancer research
6 August 2016
Research Associate at Melanoma Institute Australia, Dr James Wilmott, was awarded the Wildfire Award at last night's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The 'Wildfire' Highly Cited Publication Award is given to a NSW researcher who has made a significant difference to cancer research, care or practice through authoring a highly cited publication that is expected to significantly influence cancer control or further research.
His publication ‘Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma external’ is being used by pathology departments around the world to triage patients into lifesaving personalised medicines.
Some patients only have days to live without intervention and cannot wait for routine molecular testing results.
The assay described in the publication allows patients who could die waiting to be tested and treated with lifesaving drugs.
Dr Wilmott has authored more than 50 manuscripts which have been cited over 1400 times. His research interests are biomarker studies of patients treated with targeted therapies and he is currently working as the Project Manager for the Australian Melanoma Genome Project.
As part of the prestigious award, Dr Wilmott will be granted $20,000 to future research endeavours.
Previous winners of the Wildfire Award from MIA include Prof Georgina Long (in 2014) and A/Prof Pascale Guitera (in 2013).
Throughout January our community created, hosted and participated in some amazing events, each of them helping us on our quest to reach zero deaths from melanoma.
Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
It’s time again to say thank you to our amazing community fundraisers!
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.
It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.